The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin

Mutation Research - DNA Repair

Volumn 409, Issue 3, 1998, Pages 147-162

  Yokote, Hideyuki ^a,b   Nishio, Kazuto ^a   Arioka, Hitoshi ^a   Kurokawa, Hirokazu ^a   Fukuoka, Kazuya ^a   Fukumoto, Hisao ^a   Ishida, Tomoyuki ^a   Terada, Tomoaki ^b   Itakura, Toru ^b   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

C terminus; DNA repair; Duocarmycin; p53

Indexed keywords

CAMPTOTHECIN; DUOCARMYCIN A; ETOPOSIDE; FLUOROURACIL; GLUTATHIONE; MITOMYCIN C; PACLITAXEL; PROTEIN P53; VINDESINE;

ARTICLE; CONSENSUS SEQUENCE; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA STRAND; HUMAN; MICROTUBULE; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS, ALKYLATING; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DNA, SINGLE-STRANDED; NUCLEIC ACID RENATURATION; PROTEIN BINDING; PYRROLIDINONES; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031794421     PISSN: 09218777     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0921-8777(98)00052-4     Document Type: Article

References (53)

1. Bakalkin G., Yakovleva T., Selivanova G., Magnusson K.P., Szekely L., Kiseleva E., Klein G., Terenius L., Wiman K.G. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl. Acad. Sci. USA. 91:1994;413-417.
2. Bargonetti J., Friedman P.N., Kern S.E., Vogelstein B., Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell. 65:1991;1083-1091.
3. Bargonetti J., Manfredi J.J., Chen X., Marshak D.R., Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Develop. 7:1993;2565-2574.
4. Boger D.L., Johnson D.S. Demonstration of a pronounced effect of noncovalent binding selectivity on the (+)-CC-1065 DNA alkylation and identification of the pharmacophore of the alkylation subunit. Proc. Natl. Acad. Sci. USA. 92:1995;3642-3649.
5. Boger D.L., Johnson D.S., Palanki M.S., Kitos P.A., Chang J., Dowell P. Evaluation of functional analogs of CC-1065 and the duocarmycins incorporating the cross-linking 9α-chloromethyl-1,2,9,9α-tetrahydrocyclopropa[c]benz[e]indol-4-on e (C2BI) alkylation subunit. Bioorganic Med. Chem. 1:1993;27-38.
6. Boger D.L., Zarrinmayeh H., Munk S.A., Kitos P.A., Suntornwat O. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl. Acad. Sci. USA. 88:1991;1431-1435.
7. Brain R., Jenkins J.R. Human p53 directs DNA strand reassociation and is photolabelled by 8-azido ATP. Oncogene. 9:1994;1775-1780.
8. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849-852.
9. Demers G.W., Foster S.A., Halbert C.L., Galloway D.A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16E7. Proc. Natl. Acad. Sci. USA. 91:1994;4382-4386.
10. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.J., Butel J.S., Bradley A. Nature. 356:1992;215-221.
11. el D.W., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
12. Fields S., Jang S.K. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1990;1046-1049.
13. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
14. Fukasawa K., Choi T., Kuriyama R., Rulong S., Vande W.G. Abnormal centrosome amplification in the absence of p53. Science. 271:1996;1744-1747.
15. Funk W.D., Pak D.T., Karas R.H., Wright W.E., Shay J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:1992;2866-2871.
16. Halazonetis T.D., Davis L.J., Kandil A.N. Wild-type p53 adopts a mutant-like conformation when bound to DNA. EMBO J. 12:1993;1021-1028.
17. Hall P.A., McKee P.H., Menage H.D., Dover R., Lane D.P. High levels of p53 protein in VC-irradiated normal human skin. Oncogene. 8:1993;203-207.
18. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 71:1992;543-546.
19. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
20. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
21. Ichimura M., Ogawa T., Katsumata S., Takahashi K., Takahashi I., Nakano H. Duocarmycins, new antitumor antibiotics produced by Streptomyces; producing organisms and improved production. J. Antibiot. 44:1991;1045-1053.
22. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res. 51:1991;6304-6311.
23. Kastan M.B., Radin A.I., Kuerbitz S.J., Onyekwere O., Wolkow C.A., Civin C.I., Stone K.D., Woo T., Ravindranath Y., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;4279-4286.
24. Kastan M.B., Zhan Q., el D.W., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
25. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252:1991;1708-1711.
26. Kobayashi E., Okamoto A., Asada M., Okabe M., Nagamura S., Asai A., Saito H., Gomi K., Hirata T. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res. 54:1994;2404-2410.
27. Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491-7495.
28. Lane D.P. Cancer. p53, Guardian of the genome. Nature. 358:1992;15-16.
29. Lee J.M., Bernstein A. p53 Mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA. 90:1993;5742-5746.
30. Lin J., Chen J., Elenbaas B., Levine A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcription activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Develop. 8:1994;1235-1246.
31. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p53 Status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
32. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. Cell. 74:1993;957-967.
33. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 Is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
34. Lu X., Park S.H., Thompson T.C., Lane D.P. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell. 70:1992;153-161.
35. Nelson W.G., Kastan M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1994;1815-1823.
36. Oberosler P., Hloch P., Ramsperger U., Stahl H. p53-Catalyzed annealing of complementary single-stranded nucleic acids. EMBO J. 12:1993;2389-2396.
37. Ogasawara H., Nishio K., Kanzawa F., Lee Y.S., Funayama Y., Ohira T., Kuraishi Y., Isogai Y., Saijo N. A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells. Jpn. J. Cancer Res. 86:1995;124-129.
38. Ogasawara H., Nishio K., Takeda Y., Ohmori T., Kubota N., Funayama Y., Ohira T., Kuraishi Y., Isogai Y., Saijo N. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn. J. Cancer Res. 85:1994;418-425.
39. Pavletich N.P., Chambers K.A., Pabo C.O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Develop. 7:1993;2556-2564.
40. Perry M.E., Piette J., Zawadzki J.A., Harvey D., Levine A.J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA. 90:1993;11623-11627.
41. Price B.D., Calderwood S.K. Increased sequence-specific p53-DNA binding activity after DNA damage is attenuated by phorbol esters. Oncogene. 8:1993;3055-3062.
42. Reed M., Woelker B., Wang P., Wang Y., Anderson M.E., Tegtmeyer P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA. 92:1995;9455-9459.
43. Sancar A. Mechanisms of DNA excision repair. Science. 266:1994;1954-1956.
44. Shaw P., Bovey R., Tardy S., Sahli R., Sordat B., Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA. 89:1992;4495-4499.
45. Szekely L., Selivanova G., Magnusson K.P., Klein G., Wiman K.G. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA. 90:1993;5455-5459.
46. Tishler R.B., Calderwood S.K., Coleman C.N., Price B.D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 53:1993;2212-2216.
47. Tishler R.B., Lamppu D.M., Park S., Price B.D. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of trnascriptionally active p53. Cancer Res. 55:1995;6021-6025.
48. Wahl A.F., Donaldson K.L., Fairchild C., Lee F.Y., Foster S.A., Demers G.W., Galloway D.A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med. 2:1996;72-79.
49. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA. 91:1994;2230-2234.
50. Wang X.W., Yeh H., Schaeffer L., Roy R., Moncollin V., Egly J.M., Wang Z., Freidberg E.C., Evans M.K., Taffe B.G.et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet. 10:1995;188-195.
51. Wang Y., Reed M., Wang P., Stenger J.E., Mayr G., Anderson M.E., Schwedes J.F., Tegtmeyer P. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Develop. 7:1993;2575-2586.
52. Wu X., Levine A.J. p53 And E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA. 91:1994;3602-3606.
53. 32P ]ddATP Gene. 27:1984;309-313.